Affordable Care Act, Affordability, Behavioral Health, Health Equity, Maternal Health, Surprise Billing, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 Commercialization, Telehealth-extending flexibilities, Transparency & PBMs (S. 127, S. 1339, S. 3430, H.R. 3651, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4527, H.R. 4822, H.R. 5378), Provider Directories, Insulin Affordability (S. 1269, S. 954), Prescription Drugs (S. 150, S. 1067, S. 1114, S. 2305)
Medicare Advantage (star ratings, Health Equity Index, supplemental benefits, 2025 Rate Notice), Medicare Prior Authorization and electronic Prior Authorization, Implementation of the Inflation Reduction Act, Provider Directories (S. 3430, Sec. 109), Transparency & PBMs (H.R. 3561, H.R. 5378, H.R. 4822), Site Neutrality & Provider Billing (S. 1869, H.R. 3417, H.R. 5378, Sec. 203 and Sec. 204)
Duration: February 19, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Pharmacy , Science/Technology , Insurance
Spending: about $9,810,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Alison Esquea Deputy Leg. Director, Sen. John Kerry; Deputy Leg. Director, Sen. Mo Cowan
Ryne Carney Intern - Rep. Ed Perlmutter
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 12.
Original Filing: 301548707.xml
Lobbying Issues
Affordable Care Act, Affordability, Behavioral Health, Health Equity, Maternal Health, Surprise Billing, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 Commercialization, Telehealth-extending flexibilities, Transparency & PBMs (S. 127, S. 1339, S. 3430, H.R. 3651, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4527, H.R. 4822, H.R. 5378), Provider Directories, Insulin Affordability (S. 1269, S. 954), Prescription Drugs (S. 150, S. 1067, S. 1114, S. 2305)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (star ratings, Health Equity Index, supplemental benefits, 2025 Rate Notice), Medicare Prior Authorization and electronic Prior Authorization, Implementation of the Inflation Reduction Act, Provider Directories (S. 3430, Sec. 109), Transparency & PBMs (H.R. 3561, H.R. 5378, H.R. 4822), Site Neutrality & Provider Billing (S. 1869, H.R. 3417, H.R. 5378, Sec. 203 and Sec. 204)
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301537758.xml
Lobbying Issues
Affordable Care Act, Affordability,
Behavioral Health, Health Equity, Maternal Health, Surprise Billing, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 Commercialization, Telehealth-extending flexibilities, Transparency & PBMs (S. 127, S. 1339, H.R. 3651, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4527, H.R. 4822, H.R. 5378), Provider Directories, Insulin Affordability (S. 1269, S. 954), Prescription Drugs (S. 6, S. 150, S. 1067, S. 1114, S. 2305)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (star ratings, Health Equity Index, supplemental benefits), Medicare Prior Authorization, Implementation of the Inflation Reduction Act, Provider Directories (S. 3430), Transparency & PBMs (H.R. 3561, H.R. 5378, H.R. 4822), Site Neutrality & Provider Billing (S. 1869 & H.R. 3417)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301507438.xml
Lobbying Issues
Affordable Care Act, Behavioral Health, Health Equity, Maternal Health, Implementation of No Surprises Act, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 Commercialization, Telehealth-extending flexibilities, Pharmacy Benefit Managers (S. 127, S. 1339), Provider Directories, Insulin Affordability (S. 1269, S. 954), Promoting Access to Treatments and Increasing Extremely Needed Transparency (H.R. 3561), Lower Costs More Transparency Act (H.R. 5378), Prescription Drugs (S. 6, S. 1114, S. 1067, S. 150), Health Care Price Transparency Act of 2023 (H.R. 4822)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (CY 2024 Rate Announcement, CY 2024 Technical Rule, MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization, Implementation of the Inflation Reduction Act, Provider Directories, Pharmacy Benefit Managers (S. 2973), Promoting Access to Treatments and Increasing Extremely Needed Transparency (H.R. 3561), Lower Costs More Transparency Act (H.R. 5378), Site Neutral Hospital Billing (S. 1869, H.R. 3417), Health Care Price Transparency Act of 2023 (H.R. 4822)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301489686.xml
Lobbying Issues
Affordable Care Act, Behavioral Health, Health Equity, Maternal Health, Implementation of No Surprises Act, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 Commercialization, Telehealth-extending flexibilities, Pharmacy Benefit Managers (S. 127, S. 1339), Insulin Affordability (S. 1269, S. 954), Promoting Access to Treatments and Increasing Extremely Needed Transparency (H.R. 3561), Site Neutral Hospital Billing (S. 1869, H.R. 3417)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (CY 2024 Rate Announcement, CY 2024 Technical Rule, MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization, Implementation of the Inflation Reduction Act, Provider Directories
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 18, 2023.
Original Filing: 301455148.xml
Lobbying Issues
Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (S. 923), Health Equity, Maternal Health, Implementation of No Surprises Act, Health IT, Interoperability, Value-Based Care, Health Care Innovation, COVID-19 PHE Transition (Medicaid Redeterminations, Commercialization of COVID-19 Vaccines & Therapeutics), HIPAA and Privacy, Telehealth, Public Option, Pharmacy Benefit Managers (S. 113, S. 127), Insulin Affordability (S. 146, S. 954, S. 727, H.R. 1485), Transparency (H.R. 410, S. 1130), Affordability (site neutral payment policies)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (CY 2024 Rate Announcement, CY 2024 Technical Rule, MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization, Implementation of the Inflation Reduction Act, Telehealth, Behavioral Health (S. 923), COVID-19 PHE Transition (Medicaid Redeterminations, Commercialization of COVID-19 Vaccines & Therapeutics)
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Jan. 18, 2023.
Original Filing: 301430555.xml
Lobbying Issues
Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (H.R. 7666, H.R. 7780, House Ways and Means Committee prints 117-4 & 117-5), Health Equity, Maternal Health (H.R. 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Inflation Reduction Act (P.L. 117-169), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319, COVID-19 Testing, OTC COVID Testing & Vaccine Strategy), HIPAA and Privacy, Telehealth, Public Option, Consolidated Appropriations Act, 2023 (P.L. 117-403).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization (H.R. 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (H.R. 3, H.R. 19, S. 2164), Insulin Affordability (S. 3700, H.R. 6833), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (H.R. 2166, S. 150), Inflation Reduction Act (P.L. 117-169), Third Party Marketing Organization Requirements, Behavioral Health (House Ways and Means Committee prints 117-1 & 117-2), Consolidated Appropriations Act, 2023 (P.L. 117-403).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Oct. 17, 2022.
Original Filing: 301405661.xml
Lobbying Issues
Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (H.R. 7666, H.R. 7780, House Ways and Means Committee prints 117-4 & 117-5), Health Equity, Maternal Health (H.R. 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Inflation Reduction Act (P.L. 117-169), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319, COVID-19 Testing, OTC COVID Testing & Vaccine Strategy), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization (H.R. 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (H.R. 3, H.R. 19, S. 2164), Insulin Affordability (S. 3700, H.R. 6833), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (H.R. 2166, S. 150), Inflation Reduction Act (P.L. 117-169), Third Party Marketing Organization Requirements, Behavioral Health (House Ways and Means Committee prints 117-1 & 117-2)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on July 14, 2022.
Original Filing: 301380099.xml
Lobbying Issues
Affordable Care Act, Extending ARPA Subsidies, Individual Market Reform, Behavioral Health (H.R. 7666), Health Equity, Maternal Health (H.R. 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319, COVID-19 Testing, OTC COVID Testing & Vaccine Strategy), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization (H.R. 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (H.R. 3, H.R. 19, S. 2164), Insulin Affordability (S. 3700, H.R. 6833), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (H.R. 2166, S. 150)
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 14, 2022.
Original Filing: 301345912.xml
Lobbying Issues
Affordable Care Act, Individual Market Reform, Behavioral Health, Health Equity, Maternal Health (HR 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319, COVID-19 Testing, OTC COVID Testing & Vaccine Strategy), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings, supplemental benefits), Medicare Prior Authorization (HR 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (HR 3, HR 19, S 2164), Insulin Affordability (S. 3700, H.R. 6833), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (HR 2166, S. 150)
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Jan. 14, 2022.
Original Filing: 301322442.xml
Lobbying Issues
Affordable Care Act, Individual Market Reform, Behavioral Health, Health Equity, Maternal Health (HR 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319, Testing & Vaccine Strategy), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings), Medicare Prior Authorization (HR 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (HR 3, HR 19, S 2164), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (HR 2166, S. 150)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Oct. 12, 2021.
Original Filing: 301298317.xml
Lobbying Issues
Affordable Care Act, Individual Market Reform, Behavioral Health, Health Equity, Maternal Health (HR 959, S 346), Implementation of No Surprises Act, Build Back Better Act (H. Res. 601, S. Con. Res. 14), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings), Medicare Prior Authorization (HR 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (HR 3, HR 19, S 2164), Telehealth, Build Back Better Act (H. Res. 601 & S. Con. Res. 14), Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (HR 2166, S. 150)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on July 15, 2021.
Original Filing: 301276384.xml
Lobbying Issues
Affordable Care Act, Individual Market Reform, Behavioral Health, Health Equity, Maternal Health (HR 959, S 346), Implementation of No Surprises Act, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319), HIPAA and Privacy, Telehealth, Public Option.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings), Medicare Prior Authorization (HR 3173), Prescription Drug Rebates, Medicare Part D and Part D restructuring (HR 3, HR 19, S 2164), Telehealth, Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (HR 2166, S. 150)
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 13, 2021.
Original Filing: 301252545.xml
Lobbying Issues
Affordable Care Act, Individual Market Reform, Behavioral Health, Health Equity, Maternal Health, Interoperability, Value-Based Care, Health Care Innovation, Federal Coronavirus Response (American Rescue Plan, H.R. 1319), HIPAA and Privacy, Telehealth
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, star ratings), Medicare Prior Authorization, Prescription Drug Rebates, Medicare Part D and Part D restructuring, Telehealth, Federal Coronavirus Response (American Rescue Plan, H.R. 1319), Parity for Audio-Only Risk Adjustment (HR 2166, S. 150)
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Jan. 15, 2021.
Original Filing: 301231621.xml
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Surprise Billing (S. 1895, HR 3630, HR 2328), All Payer Claims Data Bases (S. 1895, HR 2328), Transparency (S. 1895), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV) and Premium Credit Reporting, Stark and Anti-Kickback Statute, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010, H.R. 133 - the Consolidated Appropriations Act, 2021), HIPAA and Privacy, Telehealth (H.R. 5763)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, 2022 star ratings), Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3, H.R. 19, S. 3129), Telehealth, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010); Parity for Audio-Only Risk Adjustment (H.R. 7659, S. 4840).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Oct. 17, 2020.
Original Filing: 301212497.xml
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Surprise Billing (S. 1895, HR 3630, HR 2328), All Payer Claims Data Bases (S. 1895, HR 2328), Transparency (S. 1895), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV) and Premium Credit Reporting, Stark and Anti-Kickback Statute, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010), HIPAA and Privacy, Telehealth (H.R. 5763)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, 2022 star ratings), Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3, H.R. 19, S. 3129), Telehealth, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010); Parity for Audio-Only Risk Adjustment (H.R. 7659).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on July 16, 2020.
Original Filing: 301190049.xml
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Surprise Billing (S. 1895, HR 3630, HR 2328), All Payer Claims Data Bases (S. 1895, HR 2328), Transparency (S. 1895), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV), Stark and Anti-Kickback Statute, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010), HIPAA and Privacy, Telehealth (H.R. 5763)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage (MLR, risk adjustment, 2022 star ratings), Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3, H.R. 19, S. 3129), Telehealth, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748, H.R. 266, H.R. 6800, H.R. 7010)
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 18, 2020.
Original Filing: 301172000.xml
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Value-Based Care, Health Care Innovation, Surprise Billing (S. 1895, HR 3630, HR 2328), All Payer Claims Data Bases (S. 1895, HR 2328), Transparency (S. 1895), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV), Stark and Anti-Kickback Statute, Federal Coronavirus Response (H.R. 6074, H.R. 6201, H.R. 748), HIPAA and Privacy, Telehealth
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage, Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3, H.R. 19, S. 3129), Telehealth
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Jan. 17, 2020.
Original Filing: 301108376.xml
Lobbying Issues
Full repeal and 2-year delay of Health Insurance tax (S. 80, S. 172, HR 1398/ S.172, HR 1865)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Surprise Billing (S. 1895, HR 3630, HR 2328), All Payer Claims Data Bases (S. 1895, HR 2328), Transparency (S. 1895), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage, Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on Oct. 18, 2019.
Original Filing: 301069263.xml
Lobbying Issues
Full repeal and 2-year delay of Health Insurance tax (S. 80, S. 172, HR 1398)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Surprise Billing (S. 1895; HR 3630), Palliative Care (HR 647/S.2080), Health Savings Accounts (HSAs), HHS Risk Adjustment Data Validation (HHS-RADV)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage, Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring (S. 2543, H.R. 3)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on July 18, 2019.
Original Filing: 301048644.xml
Lobbying Issues
Full repeal and 2-year delay of Health Insurance tax (S. 80, S. 172, HR 1398/ S.172)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Affordable Care Act, ACA Regulations, Individual Market Reform, Transparency (S. 1895, S. 1497), Health IT, Interoperability, Surprise Billing (S. 1895; HR 3502), Palliative Care (HR 647), Health Savings Accounts (HSAs)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Advantage, Medicare Prior Authorization (HR 3107), MA Quality Payments (H.R. 2131, S. 1114), Interoperability, Prescription Drug Rebates, Medicare Part D and Part D restructuring
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, CAMBIA HEALTH SOLUTIONS had in-house lobbyists. The report was filed on April 19, 2019.
Original Filing: 301030578.xml
Lobbying Issues
Support for full repeal and 2-year delay of Health Insurance tax (S. 80, S. 172, HR 1393)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Impact of Proposed Rule on removal of safe harbor protection for rebates involving prescription pharmaceuticals
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for increased health care transparency for consumers on health care price and quality; Improve and expand access to high quality palliative care (HR 647); Continued interest and support for policies focused on more formal inclusion of family caregivers as part of an individuals caregiving team; Affordable Care Act (ACA); ACA regulations; Individual Market Reform; Short-Term Limited Duration Insurance (STLDI).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Impact of Proposed Rule by CMS on interoperability and patient access
Agencies Lobbied
U.S. Senate
Lobbying Issues
Impact of Proposed Rule by ONC on interoperability, information blocking and health IT certification; Impact of Proposed Rule by CMS on interoperability and patient access
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
CAMBIA HEALTH SOLUTIONS filed a lobbying registration on April 5, 2019 for in-house lobbying efforts, effective Feb. 19, 2019.
Original Filing: 301022955.xml
Issue(s) they said they’d lobby about: Support for full repeal and 2 yr delay of Health Insurance Tax, repeal of Cadillac tax, increased health care transparency for consumers on health care price & quality, expanded telehealth policies in Medicare & HSAs, more flexibility in Medicare Part D, market-based solutions for prescription drug prices, expansion & increased flexibility of health care accounts; Impact of Proposed Rules on removal of safe harbor protection for rebates involving prescription pharmaceuticals, interoperability & patient access, interoperability, information blocking & health IT certification, & Medicare expansion proposals; Eliminating use of copay coupons in commercial sector; Improve & expand access to high quality palliative care .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...